Skip to content

Ketamine for depression: all studies

Page 81 of 154: studies 801 to 810 of 1,534, newest first. Back to the ketamine for depression overview

Research

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.

Psychiatry Research May 1, 2024 Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al. 12 citations

Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking. Herein, we aim to inform prediction models of non-response to ketamine/esketamine in adults with TRD. This is a retrospective analysis of PHQ-9 item response data from 120 patients with TRD who received repeated doses of...

Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis.

Psychiatry Research May 1, 2024 Jinping Wang, Hui Liu, Xinchuan Wei 9 citations

This systematic review and meta-analysis aimed to evaluate the impact of intraoperative and/or postoperative esketamine application on the prevention of postpartum depression (PPD). PubMed, Embase, and Web of Science were thoroughly searched for eligible randomized controlled trials (RCTs) regarding the application of esketamine for postnatal depression prevention. Nine RCTs including 1277...

DOI: 10.1016/j.psychres.2024.115890 (opens in new tab) Full text (opens in new tab) Ketamine Postnatal depression Maternal health Mental health treatment +3

Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.

BMJ Open May 1, 2024 Ben Beaglehole, Richard Porter, Katie M. Douglas et al. 5 citations

Although short-term benefits follow parenteral ketamine for treatment-resistant major depressive disorder (TR-MDD), there are challenges that prevent routine use of ketamine by clinicians. These include acute dissociative effects of parenteral ketamine, high relapse rates following ketamine dosing and the uncertain role of psychotherapy. This randomised controlled trial (RCT) seeks to establish...

DOI: 10.1136/bmjopen-2024-084844 (opens in new tab) Full text (opens in new tab) Adult psychiatry Psychosocial intervention Depression treatment Ketamine therapy +2

Effects of ketamine on the severity of depression and anxiety following postoperative mechanical ventilation: a single-blind randomized clinical trial in Iran.

Acute and critical care May 1, 2024 Seyedbabak Mojaveraghili, Fatemeh Talebi, Sima Ghorbanoghli et al. 1 citation

In this study, we compare the effects of ketamine and the combination of midazolam and morphine on the severity of depression and anxiety in mechanically ventilated patients after discharge from the intensive care unit (ICU). This randomized single-blind clinical trial included 50 patients who were candidates for craniotomy and postoperative mechanical ventilation in the ICU of 5 Azar Teaching...

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential.

Aging and disease April 29, 2024 Qianting Deng, Emily Parker, Chongyun Wu et al. 8 citations

Depression represents a prevalent and enduring mental disorder of significant concern within the clinical domain. Extensive research indicates that depression is very complex, with many interconnected pathways involved. Most research related to depression focuses on monoamines, neurotrophic factors, the hypothalamic-pituitary-adrenal axis, tryptophan metabolism, energy metabolism, mitochondrial...

DOI: 10.14336/AD.2024.0239 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Ketamine therapy Antidepressants

A retrospective analysis of iv ketamine outcome on hospitalisations in an unselected psychiatric sample.

Acta Neuropsychiatrica April 25, 2024 Karl Sandström, Olli Kampman, Peter Asellus 1 citation

This study aims to explore the outcome with iv ketamine treatment in a real-world clinical setting, primarily measured as posttreatment days hospitalised. The psychiatric medical records of 46 patients having received iv ketamine on a psychiatric treatment indication between 2015 and 2018 were retrospectively examined. Analysis comparing the number and duration of hospital admissions before and...

Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023.

European Archives of Psychiatry and Clinical Neuroscience April 25, 2024 Li-Yuan Zhao, Guang-Fen Zhang, Xue-Jie Lou et al. 11 citations

Ketamine has demonstrated rapid and sustained antidepressant effects, marking its emergence as an innovative treatment of depression. Despite the growing number of preclinical and clinical studies exploring the antidepressant effects of ketamine and its enantiomers, a comprehensive bibliometric analysis in this field has yet to be conducted. This study employs bibliometric methods and...

A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.

The Journal of Clinical Psychiatry April 24, 2024 Gregory H Jones, Courtney M Vecera, Ana C Ruiz et al. 13 citations

Objective: Although individuals with a family history of alcohol use disorder (AUD) have a superior antidepressant response to ketamine, outcomes in patients with current AUD remain unclear. This study sought to investigate whether intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects in unipolar and bipolar depression and whether comorbid AUD conferred superior...

DOI: 10.4088/JCP.23m14974 (opens in new tab) Full text (opens in new tab) Depression Ketamine therapy Mental health treatment Substance abuse +1

Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.

Discover Mental Health April 17, 2024 Jon Berner, Animesh Acharjee 7 citations

Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF)...

DOI: 10.1007/s44192-024-00066-5 (opens in new tab) Full text (opens in new tab) Depression treatment Personalized medicine Mental health research Biomarkers

Ketamine for major depressive disorder during an inpatient psychiatric admission: Effectiveness, adverse events, and lessons learned.

Journal of Affective Disorders April 15, 2024 Benjamin D. Brody, Nana Park, Alexander Christian et al. 8 citations

Most studies examining the efficacy of ketamine for Major Depressive Disorder (MDD) have been conducted in outpatient or mixed inpatient/outpatient settings. Less is known about effectiveness and tolerability of ketamine for psychiatrically hospitalized patients. Efficacy and tolerability data from a naturalistic sample of acute inpatients may help inform institutions considering ketamine...